Copyright
©The Author(s) 2022.
World J Clin Cases. May 26, 2022; 10(15): 4785-4798
Published online May 26, 2022. doi: 10.12998/wjcc.v10.i15.4785
Published online May 26, 2022. doi: 10.12998/wjcc.v10.i15.4785
Variables | Pre-pandemic, n = 61 | Pandemic, n = 48 | Total, n = 109 | P value |
Sex (%) | 0.629 | |||
Male | 53 (86.9) | 44 (91.7) | 97 (89) | |
Female | 8 (13.1) | 4 (8.3 | 12 (11) | |
LT type | 0.017 | |||
LDLT | 54 (88.5) | 48 (100) | 102 (93.6) | |
DDLT | 7 (11.5) | 0 (0) | 7 (6.4) | |
Child score | 0.353 | |||
A | 22 (36.1) | 12 (25.0) | 34 (31.2) | |
B | 27 (44.3) | 22 (45.8) | 49 (45.0) | |
C | 12 (19.7) | 14 (29.2) | 26 (23.8) | |
Milan criteria | 0.337 | |||
Within | 36 (59.0) | 23 (47.9) | 59 (54.1) | |
Beyond | 25 (41.0) | 25 (52.1) | 50 (45.9) | |
UCSF criteria | 0.450 | |||
Within | 41 (67.2) | 28 (58.3 | 69 (63.3) | |
Beyond | 20 (32.8) | 20 (41.7) | 40 (36.7) | |
BCLC criteria | 0.429 | |||
Within | 46 (75.4) | 32 (66.7) | 78 (71.6) | |
Beyond | 15 (24.6) | 16 (33.3) | 31 (28.4) | |
Tokyo (5-5 rule) | 0.684 | |||
Within | 44 (72.1) | 32 (66.7) | 76 (69.7) | |
Beyond | 17 (27.9) | 16 (33.3) | 33 (30.3) | |
Onaca criteria | 0.293 | |||
Within | 45 (73.8) | 30 (62.5) | 75 (68.8) | |
Beyond | 16 (26.2) | 18 (37.5) | 34 (31.2) | |
CUN navara criteria | 0.450 | |||
Within | 41 (67.2) | 28 (58.3) | 69 (63.3) | |
Beyond | 20 (32.8) | 20 (41.7) | 40 (36.7) | |
Up-to-7 criteria | 0.142 | |||
Within | 46 (75.4) | 29 (60.4) | 75 (68.8) | |
Beyond | 15 (24.6) | 19 (39.4 | 34 (31.2) | |
AFP model | 0.202 | |||
Within | 45 (73.8) | 29 (60.4) | 74 (67.9) | |
Beyond | 16 (26.2) | 19 (39.6) | 35 (32.1) | |
AFP-TTD criteria | 0.223 | |||
Within | 47 (77.0) | 31 (64.6) | 78 (71.6) | |
Beyond | 14 (23.0) | 17 (35.4) | 31 (28.4) | |
Expanded Malatya criteria | 0.826 | |||
Within | 43 (70.5) | 32 (66.7) | 75 (68.8) | |
Beyond | 18 (29.5) | 16 (33.3) | 34 (31.2) | |
5-5-500 rule | 0.449 | |||
Within | 43 (70.5) | 30 (62.5) | 73 (67.0) | |
Beyond | 18 (29.5) | 18 (37.5) | 36 (33.0) | |
Samsung criteria | 0.229 | |||
Within | 47 (77.0) | 32 (66.7) | 79 (72.5) | |
Beyond | 14 (23.0) | 16 (33.3 | 30 (27.5) | |
Macrovascular invasion | 0.284 | |||
Present | 7 (11.5) | 10 (20.8) | 17 (15.6) | |
Absent | 54 (88.5) | 38 (79.2) | 92 (84.4) | |
Tumor differentiation | 0.066 | |||
Well | 31 (50.8) | 20 (41.7) | 51 (46.8) | |
Moderate | 23 (37.7) | 14 (29.2) | 37 (33.9) | |
Poor | 7 (11.5) | 14 (29.2) | 21 (19.3) | |
Lympho-vascular invasion | 0.019 | |||
Present | 20 (32.8) | 26 (55.3) | 46 (42.6) | |
Absent | 41 (67.2) | 21 (44.7) | 62 (57.4) | |
Perineural invasion | 0.435 | |||
Present | 0 (0.0) | 1 (2.1) | 1 (0.9) | |
Absent | 61 (100) | 46 (97.9) | 108 (98.2) | |
Capsular inasion | 0.651 | |||
Present | 2 (3.3) | 3 (6.4) | 5 (4.6) | |
Absent | 59 (96.7) | 44 (93.6) | 103 (94.5) | |
Tumor necrosis | 0.526 | |||
Present | 16 (26.2) | 9 (19.1) | 25 (22.9) | |
Absent | 45 (73.8) | 38 (80.9) | 83 (76.1) | |
Locoregional therapy ascites | 1.000 | |||
Yes | 16 (26.2) | 12 (25.0) | 28 (25.7) | |
No | 45 (73.8) | 36 (75.0) | 81 (74.3) | |
Ascites | 0.113 | |||
Mild | 32 (52.5) | 25 (52.1) | 57 (52.3) | |
Moderate | 22 (36.1) | 11 (22.9) | 33 (30.3) | |
Massive | 7 (11.5) | 12 (25.0) | 19 (17.4) | |
Outcome | 0.953 | |||
Alive | 52 (85.2) | 42 (87.5) | 94 (86.2) | |
Dead | 9 (14.8) | 6 (12.5) | 15 (13.8) | |
Recurrence | 0.693 | |||
Yes | 4 (6.6) | 2 (4.2) | 6 (5.5) | |
No | 57 (93.4) | 46 (95.8) | 103 (64.5) |
- Citation: Akbulut S, Sahin TT, Ince V, Yilmaz S. Impact of COVID-19 pandemic on clinicopathological features of transplant recipients with hepatocellular carcinoma: A case-control study. World J Clin Cases 2022; 10(15): 4785-4798
- URL: https://www.wjgnet.com/2307-8960/full/v10/i15/4785.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i15.4785